AbbVie Inc stock page - price, fundamentals, dividends - iOCharts

ABBV

116.51
-2.15 (-1.81%)
AbbVie Inc (NYSE, USD)
Healthcare >
Drug Manufacturers-General
Market cap
205.98B
Ent value
329.07B
Price/Sales
4.50
Price/Book
15.17
Div yield
4.46%
Div growth
18.50%
Growth years
9
FCF payout
45.37%
Trailing P/E
44.62
Forward P/E
8.39
PEG
5.40
EPS growth
36.80%
1 year return
11.81%
3 year return
10.55%
5 year return
14.13%
10 year return
-
Last updated: 2021-11-26

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open117.61
Daily high118.11
Daily low115.83
Daily Volume4.27M
All-time high123.21
1y analyst estimate127.78
Beta0.80
EPS (TTM)2.62
Dividend per share5.20
Ex-div date14 Jul 2021
Next earnings date29 Oct 2021

Downside potential

Loading...
Downside potential data
ABBVS&P500
Current price drop from All-time high-3.69%-0.06%
Highest price drop-48.88%-56.47%
Date of highest drop15 Aug 20199 Mar 2009
Avg drop from high-14.73%-11.41%
Avg time to new high21 days12 days
Max time to new high967 days1805 days

BUSINESS INSIGHT

Revenues per Product Category ($M)

Loading...
Company comments

AbbVie was created through a spinoff from Abbott Laboratories in 2013

Humira is the world’s #1 global pharmaceutical product by a large margin

AbbVie acquired Allergan, the maker of Botox in 2020, hence the huge jump in revenues and the change in the segment classifications

Geographic Revenues ($M)

Loading...

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share5.20
Dividend yield4.46%
Payout frequencyQuarterly
Maximum yield7.32%
Average yield4.65%
Minimum yield2.77%
Discount to avg yield-4.17%
Upside potential-4.00%
Yield as % of max yield60.99%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield4.46%
Current yield distribution59.05%
Yield at 100% (Min)2.77%
Yield at 90%3.45%
Yield at 80%3.88%
Yield at 50% (Median)4.76%
Yield at 20%5.39%
Yield at 10%5.77%
Yield at 0% (Max)7.32%

Dividend per share

Loading...
Dividend per share data
Years of growth9 years
CCC statusDividend Challenger
Dividend per share5.20
Payout frequencyQuarterly
Ex-div date14 Jul 2021
EPS (TTM)2.62
EPS (1y forward)13.88
EPS growth (5y)36.80%
EPS growth (5y forward)8.27%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
ABBVS&P500
DGR MR10.17%7.68%
DGR TTM10.20%-2.66%
DGR 3 years22.62%5.82%
DGR 5 years18.50%6.23%
DGR 10 years-9.64%
DGR 15 years-6.71%
Time since last change announced393 days
EPS growth (5y)36.80%
EPS growth (5y forward)8.27%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM167.16%45.37%
Average--
Forward37.46%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E44.62
Price to OCF11.71
Price to FCF12.11
Price to EBITDA20.87
EV to EBITDA33.34

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.50
Price to Book15.17
EV to Sales7.18

FINANCIALS

Per share

Loading...
Per share data
Current share count1.77B
EPS (TTM)2.62
FCF per share (TTM)9.63

Income statement

Loading...
Income statement data
Revenue (TTM)45.80B
Gross profit (TTM)30.42B
Operating income (TTM)11.66B
Net income (TTM)4.62B
EPS (TTM)2.62
EPS (1y forward)13.88

Margins

Loading...
Margins data
Gross margin (TTM)66.41%
Operating margin (TTM)25.46%
Profit margin (TTM)10.08%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash12.18B
Net receivables9.28B
Total current assets28.96B
Goodwill32.30B
Intangible assets77.46B
Property, plant and equipment0.00
Total assets148.86B
Accounts payable21.86B
Short/Current long term debt80.72B
Total current liabilities28.53B
Total liabilities135.28B
Shareholder's equity13.58B
Net tangible assets-99.17B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)17.59B
Capital expenditures (TTM)581.52M
Free cash flow (TTM)17.01B
Dividends paid (TTM)7.72B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity35.24%
Return on Assets3.07%
Return on Invested Capital4.66%
Cash Return on Invested Capital17.15%
COMPANY DETAILS
ABBV (AbbVie Inc) company logo
Marketcap
205.98B
Marketcap category
Large-cap
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Employees
50000
SEC filings
CEO
Richard Gonzalez
Country
USA
City
North Chicago
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Buffett is taking profits off the table. It might be time to do the opposite.
November 26, 2021
In this article, we discuss the 10 stocks that Warren Buffett is selling. If you want to skip our detailed analysis of these stocks, go directly to Warren Buffett is Selling These 5 Stocks. Warren Buf...
November 25, 2021
REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.
November 23, 2021
AbbVie (NYSE: ABBV) will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 2, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael,...
November 23, 2021
AbbVie (NYSE: ABBV) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on Wednesday, December 1, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Micha...
November 23, 2021
SocGen sees AbbVie 'executing better than we anticipated' in the 'crucial' areas of immuno-inflammation and aesthetics.
November 23, 2021
Income investors are facing negative real returns as inflation rates soar. Not only is wage growth falling behind inflation, but cash savings are earning almost nothing in bank accounts. Investors who...
November 22, 2021
AbbVie may be able to provide relief to the income investor struggling to find sanely valued stocks with safe dividends.
November 21, 2021
Brookfield Renewable's dividend yield of more than 3% is also quite attractive. My Motley Fool colleague Jason Hall recently went with Brookfield Renewable as the strongest renewable energy stock you...
November 21, 2021
In this article, we will be taking a look at 10 dividend ETFs to buy. To skip our detailed analysis of dividend investing, you can go directly to see the 5 Dividend ETFs to Buy. With a market as diver...
November 20, 2021
Next page